Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
about
Weight management in obesity - past and presentLEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesityAssociation of body mass index with mortality and functional outcome after acute ischemic stroke.Off-label drugs for weight management.The importance of weight management in type 2 diabetes mellitus.The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis.The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United KingdomInterventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis.Weight loss is still an essential intervention in obesity and its complications: a reviewAggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experienceThe prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis.Paternal metabolic and cardiovascular risk factors for fetal growth restriction: a case-control study.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trialMortality rate and overweight: Overblown or underestimated? A commentary on a recent meta-analysis of the associations of BMI and mortality.Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people.Prestroke weight loss is associated with poststroke mortality among men in the Honolulu-Asia Aging Study.Pharmacotherapy for obesity: novel agents and paradigms.Why do we need drugs to treat the patient with obesity?A heart-adipose tissue connection in the regulation of energy metabolism.Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes.Approaches to obesity management.Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.Rapid Surface Enhanced Raman Scattering (SERS) Detection of Sibutramine Hydrochloride in Pharmaceutical Capsules with a β-Cyclodextrin- Ag/Polyvivnyl Alcohol Hydrogel Substrate.An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY.Obesity in primary care: prevention, management and the paradox.Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes.A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study.2014 EASO Position Statement on the Use of Anti-Obesity Drugs.Examining the association between depression and obesity during a weight management programme.Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia.A randomized controlled trial to determine the efficacy of a high carbohydrate and high protein ready-to-eat food product for weight loss.Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study.The benefits of weight loss, even if regained, in reducing cardiovascular disease: welcoming evidence!
P2860
Q26774747-F5FF9327-0225-475C-85BC-643F65E4FED9Q31044140-9321E017-31F0-4F1F-96A2-4AEFB517A8B3Q33572190-D4EBBCC1-E658-45C3-92B1-0439C46FEDB4Q33747035-97020CF9-F458-4606-90C2-370D1AFB0160Q33806796-B0EEC8C2-D1B3-4496-9FF7-DA0501B03ABAQ34547464-BF552A8F-CC7C-4511-871F-FD79AD8C5C3AQ35684845-875EDCB3-1ED0-4965-8A23-7546FADDD587Q35896818-90843BD5-9E5A-4A3E-99BB-876C502ED3ABQ36001036-5CA550B6-F54D-48DB-A457-1FB0D54F31A8Q36057310-02A848A2-AD90-4075-B2A5-378B354D42CCQ36090438-B28B1289-7E04-4A70-BDDF-DBCD0FBD1DE4Q36291168-58A52319-82FB-453D-B1C5-EC5A5AABA54CQ36524299-C64E87C8-B118-40B1-9D23-0B8E10A48678Q36868226-83ECDE0B-6DAA-4F14-8C98-22F6472A4F51Q37251490-51C3CF0B-709D-4B57-9EE7-52A65FFECE46Q37277912-26D29532-DF69-4FE9-8A2F-12572D0E31FBQ37279460-14FB65D2-2B79-41D8-9050-8553C11EE9C6Q37577151-2988F83B-9F24-4E9F-93CA-4AED52841000Q37619939-0A1AF4DC-E300-45C3-887D-957E109C839EQ37712227-0C71A23B-4822-4781-9D81-6A7A5C392089Q38092069-EDBA1A78-3E85-4B86-9705-5B45B42939CDQ38168030-BA2EE834-C08A-4391-9345-E1142B13112EQ38169038-8F63C748-EF1A-4C2A-9D64-46E46D3D1B28Q38308961-AA45BAC0-2E38-49B2-B823-05D0BDDF6EB3Q38758765-C8CAA73B-B0E0-4D35-8A5C-403F98EB494CQ39118038-20A48810-9B79-46A2-83A6-7CC95C7A123BQ39414599-C6226E7E-4951-4D1D-B2B1-93943ABED473Q39444444-2A87B62D-B751-417A-98AC-E3D8AB4C0A82Q41205552-FB55F633-9AA6-4617-9265-C3DFAE129585Q41585514-6AE00D44-654F-41F2-AEF0-2E3F025FEB09Q43099548-FF5449DA-77D2-46AC-BFCB-878BB0871EE6Q43729526-9E06E09F-0E41-422B-BECF-71B0E1561AEBQ46186166-A8D08D6B-403D-412A-AB34-56E4681FDBA8Q46548666-6C149EB8-17EE-443F-B193-2EB78675EC99Q47129264-2045CFF6-55D8-43F7-B567-37BAA196F342Q47194653-BF534FF9-AAB3-4DD1-8A6C-2531F1171B22Q47279738-449FA0B5-F584-41BC-8C38-C041002DD274Q47332174-76AFC6E7-3ACB-451B-AFD8-01CF36B9E4F6Q47392852-BF543DFD-5C5D-4915-BE2F-2F93E71F8576Q47396917-05BCD2F3-6D77-4EF1-AE9E-F0A6A7DD1EE0
P2860
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Maintained intentional weight ...... scular OUTcomes (SCOUT) trial.
@en
Maintained intentional weight ...... ramine Cardiovascular OUTcomes
@nl
type
label
Maintained intentional weight ...... scular OUTcomes (SCOUT) trial.
@en
Maintained intentional weight ...... ramine Cardiovascular OUTcomes
@nl
prefLabel
Maintained intentional weight ...... scular OUTcomes (SCOUT) trial.
@en
Maintained intentional weight ...... ramine Cardiovascular OUTcomes
@nl
P2093
P2860
P50
P1476
Maintained intentional weight ...... scular OUTcomes (SCOUT) trial.
@en
P2093
A M Sharma
G M Shepherd
I D Caterson
L F Van Gaal
R J Perdok
SCOUT Investigators
U F Legler
W Coutinho
P2860
P304
P356
10.1111/J.1463-1326.2011.01554.X
P577
2012-01-18T00:00:00Z